A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs - Concepedia

Concepedia

Publication | Closed Access

A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

159

Citations

8

References

2015

Year

Shang‐Fan Yu, Bing Zheng, MaryAnn Go, Jeff Lau, Susan D. Spencer, Helga Raab, Robert Soriano, Suchit Jhunjhunwala, Robert Cohen, Michele Caruso,

Clinical Cancer Research

Abstract

These studies provide proof of concept for an anthracycline-based ADC that could be used to treat B-cell malignancies that are resistant to vc-MMAE conjugates.

References

	Year	Citations

Page 1